The set-up: Biotech stocks, as represented by the iShares Nasdaq Biotechnology ETF (IBB) , have been in a strong uptrend all year, consistently making higher highs and higher lows, but its most recent breakout puts it in overbought territory on the Relative Strength Index. The last time that happened, the IBB fell back, and that’s exactly what I expect to happen again this time.
You’re combining new highs with being overbought on the RSI, and a red candle from Tuesday; I think IBB is peaking here.
The play: If IBB has gone as high as it can for now, then it’s time to short it. Use the recent high – round it up to $337 – as a stop, but with a target back into the recent trading range, somewhere between $325 and $310, you have a great r multiple (risk-reward) on this trade. That’s precisely what most traders want, a strong technical reason to make a move, with the risk-reward outlook to make it worth the effort.
Jason Bond runs JasonBondTraining.com and is a swing trader of small-cap stocks.
You may also like
Exclusive System Tracks Wall St. Insiders
“Dollar Ace Simply Exposes Information That Wall Street Wants To Keep Quiet” Said Kyle Dennis
“One member, Wesley M., has already reported 360%+ gains in just a few short days. Don’t miss this!”
(Reserve Access Now)
“What Recession?!” Jason Bond nets $55,060 in realized profit in One Day
After going 6 for 6 on profitable trades recently, we caught up with Jason to ask how he did it.
Check out Jason’s exclusive interview revealing this tightly guarded strategy. (Watch Now)
RagingBull.com Co-Founder, Jeff Bishop, Launches High Conviction Trade Service
“We listen to our clients and we give them EXACTLY what they want, so we designed a service to deliver 1 trade, 1 time a week, with a 100%+ PROFIT TARGET, directly to your inbox every Monday before the market opens. (Read More)